|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allogeneic CAR T cell therapies for leukemia.
|
30632623 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report, we performed a meta-analysis to evaluate the efficacy and side effects of CAR-T on refractory and/or relapsed B-cell malignancies, including leukemia and lymphoma.
|
28762313 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, novel therapies such as bispecific antibodies that engage T-cells and chimeric antigen receptor T-cells (CAR-T) therapy have emerged as novel FDA-approved options that have the potential to become the new standard of care for these difficult-to-treat leukemias.
|
30716352 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a preclinical validation using a model of CD33<sup>+</sup> AML, and generated iC9 CAR T-cells co-expressing a CAR targeting the AML-associated antigen CD33 and a selectable marker (ΔCD19).ΔCD19 selected (sel.) iC9-CAR.CD33 T-cells were effective in controlling leukemia growth in vitro, and could be partially eliminated (76%) using a chemical inducer of dimerization that activates iC9.
|
30539529 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19<sup>-</sup> leukemia that aberrantly expressed the anti-CD19 CAR.
|
30275568 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD22-directed CAR-T cells have shown efficacy against leukemia as well in a recent clinical trial, representing the first alternative CAR target to approach comparable efficacy to CD19 CAR-T cells.
|
30120708 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, IFN gene therapy strongly enhances anti-tumor activity of adoptively transferred T cells engineered with tumor-specific TCR or CAR, overcoming suppressive signals in the leukemia TME.
|
30042420 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Universal CAR T Cells Treat Leukemia.
|
28193774 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas.
|
28708956 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Challenging ΔCD19 selected inducible Caspase9-CAR.CD33 T-cells with programmed-death-ligand-1 enriched leukemia blasts resulted in significant killing like observed for the programmed-death-ligand-1 negative leukemic blasts fraction.
|
27907031 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the REP T cells with BiTE RNAs showed greater efficacy in the Nalm6 leukemia model compared with REP T cells with CAR RNA (P<0.05) and resulted in complete leukemia remission.
|
27258611 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent clinical trials, engineered CAR T cells have yielded response rates as high as 90% in patients with leukemia.
|
25583785 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28.
|
19238016 |
2009 |